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Papilloma viruses (PVs) are small DNA viruses
that are widespread in nature and infect a wide va-
riety of species. PVs induce warts on the skin and
internal squamous mucosae. The first papilloma virus
was isolated from cottontail rabbits, and Rous PJB re-
ported the progression to carcinoma of virus-induced
rabbit papillomas (1). This was the first report of the
oncogenic potential of PVs.
In humans, the association of coital and venereal
factors with cervical cancer has been suggested over
the past two decades. The incidence and mortality
of cervical cancer is high among women who have
more coital partners, or whose sexual activity be-
gins at a younger age (2, 3). On the other hand,
the rarity of cervical cancer among nuns has been
confirmed by many investigators (4, 5). These facts
implicate a venereally transmitted agent in human
cervical cancer. In 1970s, Herpes Simplex Virus
type 2 (HSV-2) was considered as a potential etio-
logical factor (6). However, HSV DNA was not de-
tected in any cervical cancer (7), and a prospective
epidemiologic study failed to demonstrate any evi-
dence to support the involvement of HSV-2 infec-
tion in cervical carcinogenesis (8).
The asscociation of HPV infection with cervical
cancer was first recognized by Meisels A et al . (9).
They reported that morphological abnormalities
(koilocytosis), known as the cytopathic effect of
HPV, were often accompanied with cervical cancer.
Further support came from molecular virology which
demonstrated that HPV DNA was present in ap-
proximately 70%-80% of cervical carcinomas (10).
A recent study using PCR demonstrated that 93%
of cervical cancers contained HPV DNA (11). How-
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ever, there is an argument that the high incidence
of HPV in cervical cancer may result from the high
susceptibility of tumor cells to viral infection.
This question can be addressed through cohort
studies and experimental evidence. Prospective
epidemiologic studies have shown that, in cytologically
normal women, HPV infection precedes the devel-
opment of precancerous lesions of the cervix. For
example, in a study of 241 cytologically normal women
recruited in a sexually transmitted disease clinic,
the cumulative incidence of high-grade squamous
intraepithelial lesions at two years was 28% in
HPV-positive women compared with 3% in HPV-
negative women (12-14).
Human keratinocytes may be immortalized by
the transfection of HPV DNA and many studies have
indicated that the E6 and E7 genes of HPV are
transforming genes. Moreover, the E6 and E7 genes
in high risk HPV can immortalize primary human
keratinocytes, whereas these same genes in low
risk HPV are incapable of immortalizing primary hu-
man keratinocytes (15-18). From this epidemiological
and experimental evidence, it is now clear that high
risk HPV infection is a major risk factor for the
subsequent development of cervical cancer, although
high risk HPV infection alone is not sufficient.
STRUCTURE AND CLASSIFICATION OF HPV
PVs are members of the papovavirus family,
double-stranded DNA viruses that replicate in the
nucleus. The PV virion is 55nm in diameter and
has an icosahedral capsid made up of 72 capsomers.
The outer protein coat consists of two different pro-
teins, a major and a minor capsid protein. The 7900
base pair genome of HPV is divided into three groups :
(1) early, (2) late, and (3) control (Fig. 1). The func-
tions of the early and late genes are shown in Table 1
(19).
In addition, there is a noncoding region refered
as the Long Control Region (LCR) which regulates
the expression of the ORFs.
PVs are classified by genotype. A HPV with less
than 90% sequence homology in E6, E7 and L1 ORFs
to any of the known HPV types is classified as a new
type. There are over 90 genotypes at present and
new types are discovered every few months.
Lorincz AT et al . compared the strengths of as-
sociation between specific HPV types and different
disease severities, and classified the HPV types into
four clinical categories, “low risk” (HPV 6, 11, 42,
43, and 44), present in 20.2% of low-grade lesions
but absent in all cancers, “intermediate risk” (HPV
31, 33, 35, 51, 52, and 58), detected in 23.8% of
high-grade squamous intraepithelial lesions but
only 10.5% of cancers, “high risk” (HPV 16) associ-
ated with 47.1% of both high-grade intraepithelial
lesions and cancers, and “high risk” (HPV 18, 45,
56), found in 26.8% of invasive carcinomas but only
6.5% of high-grade intraepithelial lesions (20). HPVs
are now classified into three categories according
to their carcinogenic potential, low risk, intermedi-
ate risk, and high risk (Table 2).
Fig. 1. Linear representation of the circular HPV genome.
The HPV genome is a closed circular double-strand DNA con-
taining 7.9Kb. Transcription begins at the promotor in the long
control region (LCR). The early region genes are designated as
E1-E6 and the late region genes as L1 and L2.
Table 1. Functions of HPV genes.
ORF functions
E1
E2
E4
E5
E6
E7
L1
L2
Viral DNA replication
Regulation of viral transcription
Unknown
Transformation
Transformation, p53 degradation
Transformation, RB binding
Major capsid protein
Minor capsid protein
The genome is divided into late (L) and early (E) regions. The
L region codes two capsid proteins, the major L1 and the mi-
nor L2. L1 forms more than 95% of the capsid. The E1 and E2
regions are involved in the early stages of viral replication. The
E4 region is involved in virus maturation. The E6 and E7 re-
gions encode the viral oncoproteins.
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EPIDEMIOLOGY
Transient genital HPV infections are quite com-
mon in young sexually active women. Bauer HM
et al . studied 467 healthy university students. Using
PCR, they found that 46% of the study population
was infected with HPV (21). In Germany, Villiers
EM et al. determined the prevalence of HPV in
20,161 women to be 8.8% (22). In Japan, HPV preva-
lence is estimated to be around 10-15% (23). How-
ever, most infections are sub-clinical and resolve
themselves (24). Most lesions of low-grade squamous
intraepithelial lesions (LGSIL) are self-limiting and
also resolve themselves. A minority of women de-
velop persistent HPV infections, and some of these
persistent high risk HPV infections progress to
high-grade squamous intraepithelial lesions (HGSIL).
Some HGSIL progress to invasive carcinoma (Fig. 2).
Rozendaal L et al . studied a cohort of 1622 women
who had normal Pap smears and no previous his-
tory of cervical dysplasia. The mean follow-up time
was 40 months. Of the 86 high-risk HPV-positive
women, 6 developed CIN III, whereas it developed
in only 1 of the 1536 HPV-negative women. (25). Thus,
the epidemiological studies clearly demonstrate that
high risk HPV infection is a major risk factor for
the development of cervical cancer, however, these
studies also demonstrate that HPV infection alone
is not sufficient and cervical cancer takes a long
time to develop.
MECHANISMS
Recent experimental studies have indicated that
the E6 and E7 gene products play a critical role in
cervical carcinogenesis. The E6 of high-risk HPV
interferes with the p53 function and deregulates the
cell cycle. The E6 product binds to p53 to form a sta-
ble complex and this complex undergoes proteolysis
(26). This process requires E6AP which, in combi-
nation with E6, acts as an E3 ubiquitin ligase (27).
The E6 of high-risk HPV also down-regulates p53
acitivity by targetting the transcriptional coactivator
CBP/p300, which has a role in the cell cycle and
differentiation (28). Interactions between E6 and
many molecules have been reported, such as src
family kinase Blk (29), the mammalian homologue
of the Drosophila disc large tumor suppressor pro-
tein (hDLG) (30), and paxillin (31). However, the
roles of these protein-protein interactions with E6
is not yet clearly understood.
E7 protein shows similarities to the adenovirus
E1A, and the SV40 large T-antigen, and the host
cellular protein cyclin D1. The conserved regions
of the amino acid sequence of these proteins form
inactivating complexes with the retinoblastoma
(pRB) antioncoprotein by competitive binding to
the “retinoblastoma pocket”. This binding releases
a transcription factor, E2F. Free E2F accelerates
DNA synthesis and cell-cycle progression (32-34)
(Fig. 3).
HPV DNA exists in an extrachromosomal form
in benign and premalignant lesions. On the other
hand, HPV DNA is integrated into the host’s chro-
mosomes in cervical cancer (35, 36). This integra-
tion appears to be random because the virus genome
Table 2. Classification of HPVs.
classification of HPVs
low risk :
intermediate risk :
high risk :
60 11, 42, 43, 44
31, 33, 35, 51, 52, 58
16, 18, 45, 56
The HPV types differ in their transforming potential and
are subdivided into risk groups. Low risk types are found
in benign lesions like condyloma and are not found in
cervical cancers. High risk types are detected mainly in
carcinomas and rarely in benign and low grade lesions.
Intermediate risk types are detected in both invasive
cancers and benign lesions.
Fig. 2. The natural history of cervical intraepithelial lesions.
Schematic illustration of the natural history of cervical intraepithelial
lesions (CIN). Most mild dysplasia and 50% of severe dysplasia
are estimated to regress spontaneously. However, the pathologi-
cal criteria for dysplasia vary and the precise risk of CIN
progressing to invasive cancer is less clear.
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is integrated in different locations in different can-
cers. Integration occurs in the E1/E2 region, dis-
rupting the E2 viral genome (37). In high-risk HPV,
E2 represses the promoter from which the E6 and
E7 genes are transcribed (38). Thus, after HPV DNA
integration with disruption of the E2 gene, the ex-
pressions of the E6 and E7 genes are accelerated,
leading to the accumulation of DNA damage and
the development of cancer cells over an extended
period of time (Fig. 4).
CERVICAL INTRAEPITHELIAL NEOPLASIA
(CIN) AND HPV
Cervical intraepithelial neoplasia (CIN) is a good
model for a mutlistage disease beginning with CIN I,
progressing to CIN III (Fig. 5), and in some cases,
developing invasive carcinoma. The risks of CIN
progression are shown in Fig-2. Not all cases of
CIN progress, and most CIN I regresses spontane-
ously. An effort has been made to identify the prog-
nostic factors which govern the regression, persist-
ence and progression. In 1986, Campion MJ et al .
prospectively studied 100 women with CIN I, and
2 types of HPV, HPV16 and HPV 6 were. 22 of 39
HPV16-positive CIN I progressed to CIN III, where-
as only 4 of 61 HPV16-negative CIN I progressed
(39). The fact that persistent high-risk HPV infec-
tion is a major risk factor for CIN progression has
been confirmed by many studies (40-44). The preva-
lence of HPV in CIN in our clinic is shown on Table 3.
HPV18 is not common in Japan and the proportion
of HPV16 increases with CIN progression. The
prevalence of HPV is rather lower than reported
because only 26 types of HPV were studied in our
clinic. The prognosis of CIN in each HPV type is
shown on Table 4. It should be noted that no CIN
with HPV16 regresssed : On the contrary, 89% of CIN
without HPV regressed. No clinical management
of CIN has been established, for example, the man-
agement of CINII varies from “follow up” to “sim-
ple hysterectomy”. However, these data suggest that
CIN without HPV infection should be managed con-
servatively, whereas CIN with high-risk HPV infec-
tion may be treated with a shorter follow-up peri-
od.
HPV VACCINES
Genital HPV infection is common among young
sexually active women, and in the majority of these
women the virus resolves itself. The role of the im-
mune system in viral clearance is unknown. The
fact that HPV infection and HPV-related lesions are
more common in immunosuppressed hosts such
as those infected with HIV (45, 46) suggests that
cell-mediated immunity plays an important role. The
success of prototypic vaccines in animal models of
PV infection suggests that prophylactic vaccines
could be developed for clinical use (47, 48).
It has not been possible to produce a large amount
of PV virions in culture cells. PV virions are possibly
Fig. 3. Interactions between E7 and
E6 oncoproteins and cell cycle regula-
tors.
When DNA is damaged, the expression
of p53 is elevated, leading to cell cycle
arrest until the DNA damage is repaired.
If the damage is severe, apoptotic genes
are activated and cell death occurs. The
E6 product of HPV interferes with this
function. The cell carefully monitors cell
cycle progress. The G1/S transition con-
tains a major check-point regulated by
pRB. The E7 product forms complexes
with pRB, releasing free E2F, which allows
the cell to pass through the check-point.
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Fig. 4. Dysfunction of p53 and pRB
results in the accumulation of DNA dam-
age.
Without HPV infection, DNA damage is
repaired by p53 and pRB. When DNA
damage can not be repaired, the cell
apoptosis is induced. With HPV infec-
tion, this function of p53 and pRB is dis-
rupted, leading to the accumulation DNA
damage and the development of cervi-
cal cancer cells over a long period of
time.
Fig. 5. Progression of CIN I to CIN III.
Hematoxylin and eosin-stained histology of CIN. CIN is divided into three categories according to the extent of parabasal
hyperplasia.
H. Furumoto et al. HPV and cervical cancer１２８
not suitable for vaccines because they contain the
oncogenic genome. Thus, most studies have been
carried out using a recombinant viral protein. How-
ever, recombinant subunit vaccines based on the
major capsid protein L1 were of limited effectiveness
in animal models. The breakthrough was made by
Kirnbauer et al . who discovered that L1 self-assembles
into virus-like particles (VLPs) when expressed at
high levels in cultured insect cells, and VLPs in-
duced the production of neutralizing antibodies to
conformational epitopes (49). Moreover, vaccination
with VLPs has been shown to protect against ex-
perimental infection in animal models (50, 51). These
encouraging results in animal models have encour-
aged several commercial and public institutions to
undertake clinical trials of VLP-based vaccines. Schiller
JT et al . reported the preliminary results of the phase
I trials conducted at Johns Hopkins University.
Seventy-two men and women were enrolled, who
had four or fewer sex partners. They were randomized
into 10 µg or 50 µg VLPs and a placebo with or with-
out adjuvant. The clinical grade VLPs were purified
from HPV16 L1 recombinant baculovirus-infected
Sf-9 insect cells. All the vaccinees receiving VLP
were seroconverted for one month, as measured
in a VLP-based IgG ELISA, whereas none of the
placebo-vaccinated subjects was seroconverted dur-
ing the course of the study. The problem is wheth-
er serum IgG antibodies alone are sufficient for pro-
tection (52).
Another approach is DNA vaccines. Recently, it
was demonstrated that an intramuscular (i.m.) in-
jection of DNA expression vectors in mice result-
ed in DNA uptake in the muscle cells and expres-
sion of the protein encoded by the DNA (53). Ulmer
JB et al . reported that an injection of plasmid DNA
encoding influenza A nucleoprotein resulted in the
generation of nucleoprotein-specific cytotoxic T cells
(CTLs) and protection from a subsequent challenge
with a heterologous strain of influenza A virus
(54). Naked DNA vaccines created by combining
one or more of the HPV surface protein genes with
plasmid DNA are under development.
It is noted that HPV E7 is a tumor rejection anti-
gen. Chen L et al. demonstrated that immunizing
mice with syngeneic nontumorigenic fibroblast-like
cells containing the HPV-16 E7 gene, conferred pro-
tection against transplanted cells from an HPV-16
E7-positive syngeneic tumor (55). The E6 and E7
oncoproteins of HPV are constitutively expressed
in cervical cancer because they are required to main-
tain the cells in a transformed state. Thus, E6 and
E7 oncoproteins are attractive targets for the immune
response and are candidates for active immunotherapy.
CTL responses are an important defense mecha-
nism against viral infection and tumors. CD8+ CTL
recognizes peptides derived from HPV-related pro-
teins presented on the MHC class I molecule at
the cell surface. These peptides usually have a length
of 8 to 11 amino acids. Ressing ME et al . studied the
immunogenicity of 9 HLA-A0201 binding peptides
encoded by HPV16 E6 and E7, and identified three
peptides which were highly immunogenic in CTL
induction in the peripheral blood mononuclear cells
(PBMC) of HLA-A0201 healthy donors. Human CTL
clones specific for these three peptides were ca-
pable of lysing the HPV16 E7-containing HLA-A0201
cervical carcinoma cell line CaSki (56). A HPV-specific
CTL response was also detected in patients with
CINIII (57), and CD4+ tumor infiltrating lymphocytes
(TIL) in cervical cancer recognize HLA-DR-restricted
peptides provided by human HPV-E7 (58).
A phase I-II clinical trial was performed involv-
ing vaccination with the HPV16 E7 peptides of pa-
tients (HLA-A0201) suffering from HPV16-positive
cervical carcinoma which was refractory to conven-
tional treatment. The vaccine consisted of two HPV
E7 peptides and one helper peptide emulsified in
Table 3. Prevalence of HPV types in CIN and invasive cervi-
cal cancer.
HPV n 16 58 52 others negative
CIN I
CIN II
CIN III
invasive
80
44
64
29
10%
16%
28%
38%
15%
23%
16%
3%
20%
11%
16%
14%
34%
39%
27%
31%
21%
11%
14%
14%
Types 16, 58, and 52 are common and type 18 is infrequent in
Japan, whereas type 18 is common in Western countries. The
prevalence of type 16 is elevated with the progression of CIN.
This behavior is characteristic of high risk HPV and type 16 is
the most important single type. Types 58 and 52 are classified
as intermediate risk.
Table 4. Relationship between HPV types and the prognosis
of CIN.
n progress persistent regress
HPV16
HPV58
HPV52
others
negative
16
20
17
41
27
44%
25%
6%
12%
0%
56%
40%
47%
32%
11%
0%
35%
47%
56%
89%
It is noted that no patient with HPV16 infection regressed.
Conversely, 89% of HPV negative patients regressed. Infection
with high-risk HPV is the major prognostic factor of CIN.
The Journal of Medical Investigation Vol. 49 2002 １２９
adjuvant. No adverse side-effects were observed.
Of 19 patients enrolled, 2 were stable for one year
after the vaccination, 15 showed progressive disease,
and 2 showed tumor-regression after chemotherapy
following the vaccination (59). Another phase I trial
of peptide vaccine was conducted by Munderspach
L, et al . Eighteen women with high grade cervical
and vulvar intraepithelial neoplasia, who were
HPV16 and HLA-A2 positive, were treated with a
vaccine consisting of a 9-amino acid peptide from
amino acids 12-20 encoded by the E7 gene emulsified
with incomplete Freund’s adjuvant. Only 3 of 18
patients cleared their dysplasia, but increased dendritic
cell infiltrate was observed in 6 of 6 patients tested
(60). Adams M et al . reported that the intradermal
administration of live vaccinia virus HPV16 and 18
E6/E7 construct induced a clinical response in 1/3
advanced cervical cancer and 3/12 CIN III (61).
These results were preliminary but promising.
Dendritic cells (DC) are believed to be critical
for the induction of CTL responses. Numerous
studies have been conducted using peptide-, tumor
lysate-pulsed, and genetically engineered DC for
the induction of antitumor immunity (62-65). Tuting
et al . genetically modified DC by particle-mediated
transfer of the HPV16 E7 gene. The i.v. injection of
these genetically modified DC induced antigen-specific
CD8+ CTL in vivo and promoted the rejection of a
subsequent, normally lethal challenge with an
HPV16-transformed tumor cell line (66). The DC-based
immunotherapy was successful in animal models
(67), but only a few preliminary studies have been
reported in humans. Schoell WMJ et al. demon-
strated that CTL activity could be induced by the
co-culture of PBMC and HPV16 E711-20 peptide-pulsed
DC in vitro (68). CTL activity could also be induced
by co-culture with DC transfected with the HPV16
E7 gene by an adeno-associated virus (AAV) vec-
tor (69). Santin AD et al . reported a case with multi-
ple lung metastasis secondary to recurrent HPV
18-associated cervical adenocarcinma. DC pulsed
with HPV18 E7 oncoprotein were administered
subcutaneously. She received 14 vaccinations with
low-dose interleukin-2, and CT scans showed no
evidence of tumor progression during 13 months
of therapy. (70).
The studies on DC-based immunotherapy in hu-
mans are preliminary and unsatisfactory, however, fu-
ture refinements of this strategy to boost antigen-specific
immunity should be explored.
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